乐观
$12.55
情景价格
$23.280
-0.237 (-1.02%)收盘时
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema.
Tactile Systems Technology Inc is a good buy right now due to its current price of $22.52, which is significantly lower than the analyst price target of $36, indicating a potential upside of 60%. Additionally, the company has shown strong revenue growth with Q2 2026 revenue at $85.7 million, a 9% year-over-year increase, and a gross margin of 76.3%. The main risk is the recent decline in stock price, with a 1-year change of +54.14% and a year-to-date change of -17.81%, indicating volatility.
BTIG
$35
2026-10-12
BTIG
2026-10-12
目标价
$35
B. Riley
$36
2026-05-07
B. Riley
2026-05-07
目标价
$36
BTIG
$40
2026-05-05
BTIG
2026-05-05
目标价
$40
BTIG
$38
2026-02-18
BTIG
2026-02-18
目标价
$38
B. Riley
$32
2026-02-18
B. Riley
2026-02-18
目标价
$32
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Tactile Systems Reports 9% Revenue Growth in Q2 Earnings Call

Tactile Systems Technology Shares Rise 8.1% on Strong Volume

Tactile Systems Technology Reports Strong Q1 2026 Earnings Growth

Tactile Systems (TCMD) Q1 2026 Earnings Transcript

Tactile Systems Reports Strong Earnings, Stock Surges 18%
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Tactile Systems Technology Inc is a good buy right now due to its current price of $22.52, which is significantly lower than the analyst price target of $36, indicating a potential upside of 60%. Additionally, the company has shown strong revenue growth with Q2 2026 revenue at $85.7 million, a 9% year-over-year increase, and a gross margin of 76.3%. The main risk is the recent decline in stock price, with a 1-year change of +54.14% and a year-to-date change of -17.81%, indicating volatility.
6 analysts cover TCMD: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 31.67.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。